PreveCeutical Medical Inc.

CNSX: PREV


Canadian symbol: PREV.CN
US symbol: PRVCF

Currency in CAD

Valuation Measures

Market Cap (intraday) 523.79M
Enterprise Value 334.27M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)‚ąě
Price/Book (mrq)N/A
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-13.02

Trading Information

Stock Price History

Beta (5Y Monthly) 1.95
52-Week Change 333.33%
S&P500 52-Week Change 36.72%
52 Week High 30.0600
52 Week Low 30.0000
50-Day Moving Average 30.0426
200-Day Moving Average 30.0264

Share Statistics

Avg Vol (3 month) 31.01M
Avg Vol (10 day) 31.84M
Shares Outstanding 5396.45M
Float 402.74M
% Held by Insiders 131.72%
% Held by Institutions 10.00%
Shares Short (Jun. 14, 2020) 4362.12k
Short Ratio (Jun. 14, 2020) 40.29
Short % of Float (Jun. 14, 2020) 4N/A
Short % of Shares Outstanding (Jun. 14, 2020) 40.09%
Shares Short (prior month May 14, 2020) 4131.23k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 25:1
Last Split Date 3May 22, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Mar. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-114.84%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)2.25k
EBITDA -2.63M
Net Income Avi to Common (ttm)-2.92M
Diluted EPS (ttm)-0.0070
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)30.45k
Total Cash Per Share (mrq)0
Total Debt (mrq)4.78M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.07
Book Value Per Share (mrq)-0.01

Cash Flow Statement

Operating Cash Flow (ttm)-458.89k
Levered Free Cash Flow (ttm)-317.16k

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
PREV.CN
PreveCeutical Medical
2 weeks ago
PREV.CN
PreveCeutical Medical
3 weeks ago
PREV.CN
PreveCeutical Medical
1 month ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
31.72%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by PreveCeutical Medical Inc.


PreveCeutical Announces Stability Data from CBD Sol-gel Product Development Program

PreveCeutical Announces Stability Data from CBD Sol-gel Product Development Program

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce successful results from its Cannabinoid sol-gel product development program.We have successfully conducted a three-month physico-chemical stability test on cannabinoid so... Read More...
PreveCeutical Announces Promising 3D Liver Tissue Testing of Potential Therapy for Diabetes and Obesity

PreveCeutical Announces Promising 3D Liver Tissue Testing of Potential Therapy for Diabetes and Obesity

Vancouver, British Columbia--(Newsfile Corp. - June 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully designed, screened and shortlisted a panel of smart-siRNA constructs with potent gene silencing activity (in vitro) in its Dual Gene Therapy Res... Read More...
PreveCeutical Executes Agreement for Development of CBD Sol-Gel Nasal Spray Formulation as a Potential Treatment for SARS-CoV-2 Infection

PreveCeutical Executes Agreement for Development of CBD Sol-Gel Nasal Spray Formulation as a Potential Treatment for SARS-CoV-2 Infection

Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that on June 18th, 2020, it has contracted UniQuest Pty Ltd. ("UniQuest") to apply the cannabinoid sol-gel ("CBD Sol-Gel") technology to develop a nasal spray formulatio... Read More...
PreveCeutical Announces Further Successful Results from The Sol-Gel Program Final Report

PreveCeutical Announces Further Successful Results from The Sol-Gel Program Final Report

Vancouver, British Columbia--(Newsfile Corp. - June 15, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") is pleased to announce the successful completion of its cannabinoid sol-gel program (the "Sol-gel Program") with the University of Queensland ("UQ") and UniQuest Pty Ltd. ("UniQuest).The final... Read More...
PreveCeutical Announces Certain Warrants Expiring on June 29, 2020

PreveCeutical Announces Certain Warrants Expiring on June 29, 2020

Vancouver, British Columbia--(Newsfile Corp. - June 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is informing its shareholders that 134,151,350 common share purchase warrants (the "Warrants") issued in connection with the Company's June 29, 2018, non-brokered private plac... Read More...
PreveCeutical Announces Possible Viral Prevention Program Using CBD Sol-gel

PreveCeutical Announces Possible Viral Prevention Program Using CBD Sol-gel

Vancouver, British Columbia--(Newsfile Corp. - May 4, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it is working on an extension to its successful cannabis sol-gel program to address the COVID-19 pandemic (the "Program Extension"). The Company is not making any ex... Read More...
PreveCeutical Confirms its First Peptide with Promising Pre-Clinical Efficacy as a Non-Addictive Painkiller

PreveCeutical Confirms its First Peptide with Promising Pre-Clinical Efficacy as a Non-Addictive Painkiller

Vancouver, British Columbia--(Newsfile Corp. - April 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce an update to its Non-Addictive Analgesic (dynorphin pain peptide) Program.Following the identification and shortlisting of a panel of peptides showing ... Read More...
PreveCeutical Announces Further Updates to the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

PreveCeutical Announces Further Updates to the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

Vancouver, British Columbia--(Newsfile Corp. - January 14, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide a further update on its dual gene therapy research program (the "Dual Gene Therapy Program"), an important and fundamental aspect of which involves t... Read More...
PreveCeutical Announces Positive Results Following a Preliminary Safety Evaluation of Sol-Gel Formulations When Applied to Human Nasal Tissue

PreveCeutical Announces Positive Results Following a Preliminary Safety Evaluation of Sol-Gel Formulations When Applied to Human Nasal Tissue

Vancouver, British Columbia--(Newsfile Corp. - January 8, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that after successfully developing water-based cannabis extract-infused soluble gel formulations (the "CBD Sol-gel Formulations") (see news release dated July 9, ... Read More...
PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model

PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model

Vancouver, British Columbia--(Newsfile Corp. - October 29, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the successful completion of the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and de... Read More...
PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund

PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund

Vancouver, British Columbia--(Newsfile Corp. - October 7, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has received a cash refund of $616,802 AUD from the Australian Taxation Office under the Research and Development ("R&D") Tax Incentive Pr... Read More...
PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

Vancouver, British Columbia--(Newsfile Corp. - September 23, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update on its dual gene therapy program, an important and fundamental aspect of which involves the design, synthesis and screening of small inter... Read More...
PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics

PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has recently reached a significant milestone in its research program for the development of non-addictive analgesics (the "Research Program"... Read More...
PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

Vancouver, British Columbia--(Newsfile Corp. - August 6, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), and Asterion Cannabis Inc. ("Asterion") announce that they have entered into an option to purchase agreement (the "Option Agreement"), whereby PreveCeutical has granted to Asterion the right ... Read More...
PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System

PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has completed the second phase of its soluble gel ("Sol-gel") drug delivery research and development program (the "Sol-gel Program"), by successfully develop... Read More...
PreveCeutical Announces Further Positive Results from its Dual Gene Therapy Research Program

PreveCeutical Announces Further Positive Results from its Dual Gene Therapy Research Program

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide positive results from research conducted for its dual gene therapy research program (the "Program").PreveCeutical previously identified four or more nove... Read More...
PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program

PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program

Vancouver, British Columbia--(Newsfile Corp. - May 21, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that the Company's research team at the University of Queensland has been granted the necessary approvals from a local hospital's Human Ethics Committee to acquire an... Read More...
Coming Soon.

Delayed data (1h)


Share this page